CAN2109

Canwell Biotech Limited · Phase 1 active Small molecule

At a glance

Generic name	CAN2109
Sponsor	Canwell Biotech Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Intratumoral CAN2109 in Subjects With Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAN2109 CI brief — competitive landscape report
CAN2109 updates RSS · CI watch RSS
Canwell Biotech Limited portfolio CI